发明申请
US20100261637A1 PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE
审中-公开
用A-B-C-D及其治疗用途衍生的肽
- 专利标题： PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE
- 专利标题（中）： 用A-B-C-D及其治疗用途衍生的肽
-
申请号： US12676310申请日： 2008-09-05
-
公开(公告)号： US20100261637A1公开(公告)日： 2010-10-14
- 发明人: Jane Spetzler , Lauge Schäffer , Jesper Lau , Thomas Kruse , Patrick William Garibay , Søren Østergaard , Steffen Reedtz-Runge , Henning Thøgersen
- 申请人： Jane Spetzler , Lauge Schäffer , Jesper Lau , Thomas Kruse , Patrick William Garibay , Søren Østergaard , Steffen Reedtz-Runge , Henning Thøgersen
- 申请人地址： DK Bagsvaerd
- 专利权人： Novo nordisk A/S
- 当前专利权人： Novo nordisk A/S
- 当前专利权人地址： DK Bagsvaerd
- 优先权： EP07115741.6 20070905; EP08101011.8 20080128
- 国际申请： PCT/EP2008/061830 WO 20080905
- 主分类号： A61K38/26
- IPC分类号： A61K38/26 ; C07K14/00 ; A61P3/10 ; A61P3/04 ; A61P9/10
摘要：
The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.